Rohan Taylor1, Veronica Galvez2, Colleen Loo3. 1. Health Education & Training Institute, Gladesville, NSW, Research Fellow, School of Psychiatry and Black Dog Institute, University of New South Wales, Randwick, NSW; Psychiatry Registrar, Concord Centre for Mental Health, Concord, NSW, Australia. 2. Psychiatrist, School of Psychiatry, University of New South Wales, Randwick, NSW; Black Dog Institute, University of New South Wales, Randwick, NSW, Australia. 3. Professor of Psychiatry, School of Psychiatry, University of New South Wales, Randwick, NSW, and; Black Dog Institute, University of New South Wales, Randwick, NSW, and; Psychiatrist, St George Hospital, Kogarah, NSW, and; Psychiatrist, The Wesley Hospital, Kogarah, NSW, Australia.
Abstract
OBJECTIVES: Repetitive transcranial magnetic stimulation (rTMS) is increasingly being utilised as a treatment option for depression, and with this comes a need for a practical review of safety issues intended for clinicians. This article provides an overview of the current literature regarding safety issues with rTMS for depression, and provides recommendations for clinical practice. CONCLUSIONS: Overall, rTMS is a well-tolerated treatment with common side effects (such as headache or local pain at the site of stimulation) being mild. Severe adverse effects, such as seizures, hearing impairment or mania, are uncommon. Certain populations, including adolescents, pregnant women, older adults and those with metal/electronic implants, require special consideration when prescribing and monitoring treatment courses. With adequate assessment and monitoring processes, rTMS can be administered safely in a large proportion of depressed patients.
OBJECTIVES: Repetitive transcranial magnetic stimulation (rTMS) is increasingly being utilised as a treatment option for depression, and with this comes a need for a practical review of safety issues intended for clinicians. This article provides an overview of the current literature regarding safety issues with rTMS for depression, and provides recommendations for clinical practice. CONCLUSIONS: Overall, rTMS is a well-tolerated treatment with common side effects (such as headache or local pain at the site of stimulation) being mild. Severe adverse effects, such as seizures, hearing impairment or mania, are uncommon. Certain populations, including adolescents, pregnant women, older adults and those with metal/electronic implants, require special consideration when prescribing and monitoring treatment courses. With adequate assessment and monitoring processes, rTMS can be administered safely in a large proportion of depressedpatients.
Entities:
Keywords:
adverse effects; depression; rTMS; safety; transcranial magnetic stimulation
Authors: Amber N Edinoff; Tanner L Hegefeld; Murray Petersen; James C Patterson; Christopher Yossi; Jacob Slizewski; Ashley Osumi; Elyse M Cornett; Adam Kaye; Jessica S Kaye; Vijayakumar Javalkar; Omar Viswanath; Ivan Urits; Alan D Kaye Journal: Front Psychiatry Date: 2022-05-31 Impact factor: 5.435
Authors: Benjamin C Gibson; Joseph L Sanguinetti; Bashar W Badran; Alfred B Yu; Evan P Klein; Christopher C Abbott; Jeffrey T Hansberger; Vincent P Clark Journal: Front Neurol Date: 2018-11-28 Impact factor: 4.003
Authors: Rachel C Adams; Jemma Sedgmond; Leah Maizey; Christopher D Chambers; Natalia S Lawrence Journal: Nutrients Date: 2019-09-04 Impact factor: 5.717
Authors: Alisson P Trevizol; Jonathan Downar; Fidel Vila-Rodriguez; Kevin E Thorpe; Zafiris J Daskalakis; Daniel M Blumberger Journal: EClinicalMedicine Date: 2020-04-30